Financial Data and Key Metrics Changes - The company reported product revenue of $2.9 million in Q1 2026, a decrease from $3.3 million in Q1 2025, but a sequential increase of 5.5% from $2.7 million in Q4 2025 [11] - Product gross profit was $1.6 million, or 54.2% of revenue, in Q1 2026, compared to $1.9 million, or 58.9% of revenue, in the same quarter of the prior year [12] - The net loss for Q1 2026 was $1.4 million, or a loss of $0.03 per share, compared to net income of $1.8 million, or $0.06 per share, in Q1 2025 [13] Business Line Data and Key Metrics Changes - The OneRF brain ablation system saw nearly half of all ablations performed since its launch in Q1 2026, indicating strong market adoption [4] - The OneRF trigeminal nerve ablation system initiated a limited commercial launch in Q1 2026, with nine patients treated across three centers, all reporting pain relief [5][6] Market Data and Key Metrics Changes - The company is working towards receiving ISO 13485 certification to facilitate international commercialization of its technology [5] - The company attended the American Epilepsy Society meeting, showcasing its technology and receiving positive feedback from medical professionals [4] Company Strategy and Development Direction - The company is projecting fiscal year 2026 sales to be at least $10.5 million, representing a minimum 17% increase from fiscal year 2025 [3] - The company is in discussions with strategic partners for potential licensing of its technology and aims to conclude these discussions quickly [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued positive momentum from fiscal year 2025 and the progress across all programs [3] - The company is focused on capturing long-term outcomes through a registry for patients treated with its systems, which will help validate the technology's effectiveness [4][31] Other Important Information - The company appointed Jason Mills to its board of directors, bringing valuable experience from his previous roles in strategy and investment banking [10] - As of December 31, 2025, the company had cash and cash equivalents of $3.6 million and no outstanding debt [13][14] Q&A Session Summary Question: Update on trigeminal nerve ablation cases - The nine cases were performed at three centers, with all patients reporting pain relief. Discussions are ongoing with strategic partners for commercialization [20][21] Question: Expectations for operating expenses - SG&A expenses are expected to remain flat for the rest of the year, while R&D expenses may fluctuate based on project phases [23][25] Question: Clinical feedback from neurologists - Feedback indicates success in reducing seizures or eliminating them, with procedures being performed at patients' bedsides [30][32] Question: Sales and marketing responsibilities - Zimmer is responsible for all marketing and sales costs, while the company provides training and field support [35]

Financial Data and Key Metrics Changes - For the full year 2025, total adjusted constant currency revenue growth was 13% and adjusted EBITDA growth was 26% year-over-year, resulting in positive free cash flow while investing in future growth [5][17] - Total adjusted revenues for Q4 2025 were $118.3 million, up 18.5% compared to Q4 2024, with adjusted EBITDA increasing approximately 29% from $17.6 million to $22.7 million [16][17] - Adjusted EBITDA margin was 19.2% in Q4 2025, an improvement of approximately 110 basis points over the prior year [17] Business Line Data and Key Metrics Changes - Stent graft revenues grew 36% on a constant currency basis in Q4 2025, driven by AMDS in the U.S. and strong international growth [6][20] - On-X revenues increased 24% year-over-year on a constant currency basis, supported by global market share gains and new U.S. market opportunities [7][8] - Tissue processing revenue increased 6% year-over-year, while BioGlue revenues were flat compared to the same period last year [8][20] Market Data and Key Metrics Changes - Revenues in Asia Pacific increased 32%, North America increased 18%, EMEA increased 17%, and Latin America increased 9% compared to Q4 2024 [21] - Gross margins were 63% in both 2025 and 2024, with the 2024 margin negatively impacted by an idle plant charge due to a cybersecurity incident [21] Company Strategy and Development Direction - The company plans to replicate its strategy by introducing additional stent graft products from Europe to the U.S. and Japan, aiming to expand its total addressable market [7] - Key growth drivers include AMDS commercialization in the U.S., On-X heart valve data, NEXUS PMA, and the ARTISAN IDE trial [33][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth strategies, anticipating continued double-digit revenue growth and EBITDA margin expansion [14][28] - The company expects constant currency growth between 10%-14% for the full year 2026, with specific growth rates for different product lines [25][27] Other Important Information - The company recorded a $2.3 million adjustment to revenue for estimated payback obligations due to Italian government legislation, which has been excluded from adjusted revenue [18][19] - Free cash flow for the full year was approximately $1 million, despite significant investments in the business [24] Q&A Session Summary Question: Impact of Italian clawback on growth - Management clarified that the Italian payback was specific to the EMEA line and did not impact major product lines [39] Question: Sell-in versus sell-through for AMDS - Management noted that implantations are continuing to grow and emphasized the importance of positive first experiences for surgeons [42] Question: Progress on AMDS target accounts - Management indicated that they are in the early stages of account openings and expect significant growth in 2026 [46] Question: Market opportunity for NEXUS - Management described the NEXUS market as nascent, with a U.S. market opportunity of $150 million, and expressed confidence in gaining market share [50] Question: Pricing for AMDS and NEXUS - Management affirmed that the pricing assumptions for AMDS and NEXUS remain appropriate due to favorable reimbursement conditions [56] Question: CapEx plans for 2026 - Management indicated that the increased CapEx is primarily for capacity expansion for On-X and internal IT investments [75]

Core Viewpoint - Sino Medical has received the Medical Device Registration Certificate for its drug-eluting stent system, marking a significant milestone in its product development and commercialization efforts [2][4]. Group 1: Medical Device Registration Details - The product is a drug-eluting stent system composed of a drug-coated stent and a rapid exchange balloon catheter delivery system [2]. - The stent is made from L605 cobalt-chromium alloy and features a non-degradable bottom coating and a biodegradable drug coating containing rapamycin and PLGA [2][3]. - The drug dosage density is 1.20 μg/mm², with a drug loading range of 59 μg to 324 μg [2]. Group 2: Product Specifications and Usage - The stent is designed for use in blood vessels with diameters ranging from 2.25 mm to 5.00 mm and is intended to alleviate symptoms of ischemic heart disease [2][3]. - The product has a shelf life of 18 months and is sterilized using electron beam technology for single-use [2]. Group 3: Impact on the Company - The approval of the drug-eluting stent system enhances the company's product portfolio and is expected to meet diverse market demands, potentially boosting sales and core competitiveness [4]. - The product is classified as a Class III medical device, requiring further production licensing before it can be manufactured and sold [4].

Core Viewpoint - The company, Xinwei Medical (心玮医疗-B), is experiencing significant stock price appreciation and is projecting substantial revenue growth for the fiscal year ending December 31, 2025, driven by new product launches and market share gains in the ischemic stroke segment [1] Group 1: Financial Performance - Xinwei Medical expects to achieve revenue between approximately RMB 400 million and RMB 410 million, representing a year-on-year increase of at least 43.9% [1] - The company anticipates a pre-tax profit of approximately RMB 80 million, marking a turnaround from previous losses [1] - Revenue growth is attributed to the launch of new products and technologies for ischemic stroke, increased market share, and effective cost control measures [1] Group 2: Product Development - The company announced that its self-expanding intracranial drug-eluting stent registration application has been accepted by the National Medical Products Administration [1] - This stent is designed for the treatment of intracranial atherosclerotic stenosis, providing support and patency to narrowed and obstructed lumens while effectively preventing in-stent restenosis [1] - Currently, there are no similar products approved for market globally, indicating that the company is at the forefront of this product development within the industry [1]

Financial Data and Key Metrics Changes - Product revenue increased 105% to $1,700,000 in Q3 2025 compared to $800,000 in Q3 2024, with a year-to-date increase of 100% to $6,400,000 from $3,200,000 [4][13] - Product gross margins improved to 53.9% in Q3 2025 from 34.1% in Q3 2024, with gross profit rising to $900,000 from $300,000 [4][14] - Net loss improved to $1,500,000 or a loss of $0.03 per share in Q3 2025, compared to a net loss of $2,800,000 or a loss of $0.10 per share in Q3 2024 [17] - Cash and cash equivalents increased to $8,000,000 as of June 30, 2025, from $1,500,000 as of September 30, 2024 [18] Business Line Data and Key Metrics Changes - Licensing revenue of $3,000,000 was generated in the first nine months of fiscal 2025, compared to no licensing revenue in the same period of fiscal 2024, derived from an expanded agreement with Zimmer Biomet [13][14] - Total operating expenses decreased 9% to $2,800,000 in Q3 2025 compared to $3,100,000 in Q3 2024, with R&D expenses stable at $1,200,000 [15][16] Market Data and Key Metrics Changes - The company is pursuing market opportunities in pain management, including trigeminal neuralgia and lower back pain treatments, with potential revenue generation expected in late 2025 [6][7] - The spinal cord stimulation market is estimated to generate over $3,000,000,000 in annual revenue, representing a significant opportunity for the company [8] Company Strategy and Development Direction - The company aims to expand its product portfolio in pain management and other therapeutic applications, leveraging its thin film ablation technology [6][7] - Plans to initiate a post-market registry to collect outcomes data for patients treated with the 1RF ablation system, highlighting positive patient outcomes [5][6] Management's Comments on Operating Environment and Future Outlook - Management reiterated expectations of being funded through at least fiscal year 2026 based on contractual minimum orders and potential cash flow breakeven if key milestones are achieved [5][18] - The company is confident in its fiscal year 2025 guidance, expecting product revenue to be in the range of $8,000,000 to $10,000,000, representing a significant increase over fiscal year 2024 [12] Other Important Information - The company has received its first international patent for its spinal cord stimulation electrode and is in the process of securing ISO certification for international commercialization [10][11] - New hires in the management team are expected to contribute positively and bring cost savings [11] Q&A Session Summary Question: Can you provide an update on the drug delivery platform and its testing status? - The devices are currently ordered for initial bench testing, followed by animal testing, with human trials planned if animal testing is successful [21][22] Question: What is the market potential for trigeminal ablation and the physician specialties involved? - Approximately 150,000 people in the US suffer from trigeminal neuralgia, with potential procedures being similar to brain ablations, targeting the same physician specialties [25][26] Question: Can you discuss the design and target levels for spinal cord stimulation? - The therapy targets lower back pain, likely from L3, L4 to S1, with multiple components expected in the system [27][28] Question: Any outlook for 2026? - The company is not providing a forecast for 2026 at this time, but remains confident in its current range due to minimum purchase requirements from Zimmer [30]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月6日，微创心通医疗科技有限公司（02160.HK，简称"心通医疗"）发布了2024年度盈利预 告。 微创心通医疗科技有限公司 （02160.HK，简称"心通医疗"）是中国领先的医疗器械企业，专注于 结构性心脏 病领域创新的经导管及手术解决方案的研发和商业化 。作为 微创医疗科学有限公司（00853.HK）旗下子公司 ，心通医疗起源于其2009年成立的瓣膜预研项目，于2015年成立" 上海微创 心通医疗科技有限公司"，2021 年2月在香港联交所主板上市。 心通医疗VitaFlow ® 系列经导管主动脉瓣植入（TAVI）产品，凭借其独特的产品设计和优异的临床表现，已 进入中国近600家核心医院，其第二代TAVI产品VitaFlow Liberty ® 是全球唯一商业化的电动可回收TAVI产 品。 # 财务数据 心通医疗 预计2024年 亏损人民币 3000万至6000万元 ， 同比亏损收窄 87%-94% ，由此计算，公司24年 ...